Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Bifidobacterium animalis subsp. lactis BB-12 and Reduced Inflammation

Research synthesisVery low evidenceSmall effect4 studies · 4 beneficial · 0 neutral · 0 harmful

Across 4 studies (all reviews or preclinical), all reported beneficial effects of Bifidobacterium animalis subsp. lactis BB-12 on reducing inflammation, but effect sizes were predominantly small. No studies reported doses, durations, or statistically significant findings, limiting the ability to identify effective dose ranges or timeframes. Population data were insufficient to characterize specific groups.

Caveats: Evidence base is small (only 4 studies) — conclusions should be considered preliminary. All included studies are reviews or preclinical work; no human clinical trials with statistical significance are available. Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed).

Generated May 12, 2026
4 of 4 papers
Back to top